Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 655

1.

Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes.

Verma S, Wanner C, Zwiener I, Ofstad AP, George JT, Fitchett D, Zinman B; EMPA-REG OUTCOME Investigators.

J Am Coll Cardiol. 2019 Mar 5. pii: S0735-1097(19)33807-0. doi: 10.1016/j.jacc.2019.03.002. [Epub ahead of print] No abstract available.

PMID:
30885684
2.

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.

Savarese G, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, Butler J.

Circulation. 2019 Mar 12;139(11):1458-1460. doi: 10.1161/CIRCULATIONAHA.118.038339. No abstract available.

PMID:
30855996
3.

Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials.

Zoccali C, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Massy Z, Rychlık I, Soler M, Stevens K, Spasovski G, Wanner C.

Nephrol Dial Transplant. 2019 Feb 27. pii: gfz023. doi: 10.1093/ndt/gfz023. [Epub ahead of print]

PMID:
30815678
4.

Dyshidrosis is associated with reduced amplitudes in electrically evoked pain-related potentials in women with Fabry disease.

Siedler G, Káhn AK, Weidemann F, Wanner C, Sommer C, Üçeyler N.

Clin Neurophysiol. 2019 Apr;130(4):528-536. doi: 10.1016/j.clinph.2019.01.008. Epub 2019 Feb 4.

PMID:
30785009
5.

Left Ventricular Structure in Patients With Mild-to-Moderate CKD-a Magnetic Resonance Imaging Study.

Schneider MP, Scheppach JB, Raff U, Toncar S, Ritter C, Klink T, Störk S, Wanner C, Schlieper G, Saritas T, Reinartz SD, Floege J, Friedrich N, Janka R, Uder M, Schmieder RE, Eckardt KU.

Kidney Int Rep. 2018 Oct 11;4(2):267-274. doi: 10.1016/j.ekir.2018.10.004. eCollection 2019 Feb.

6.

The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.

Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, Nowak A, Oliveira JP, Pieroni M, Viana-Baptista M, Wanner C, Spada M.

Mol Genet Metab Rep. 2019 Feb 6;19:100454. doi: 10.1016/j.ymgmr.2019.100454. eCollection 2019 Jun. Review.

7.

Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.

Januzzi J, Ferreira JP, Böhm M, Kaul S, Wanner C, Brueckmann M, Petrie MC, Ofstad AP, Zeller C, George J, Fitchett D, Zannad F.

Eur J Heart Fail. 2019 Mar;21(3):386-388. doi: 10.1002/ejhf.1419. Epub 2019 Feb 14. No abstract available.

PMID:
30767353
8.

Will the FAbry STabilization indEX make its way to everyday clinical practice?

Cairns T, Wanner C.

Clin Kidney J. 2019 Feb;12(1):61-64. doi: 10.1093/ckj/sfy126. Epub 2018 Dec 24.

9.

A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.

Hammer F, Malzahn U, Donhauser J, Betz C, Schneider MP, Grupp C, Pollak N, Störk S, Wanner C, Krane V; MiREnDa Study Group.

Kidney Int. 2019 Jan 29. pii: S0085-2538(18)30906-2. doi: 10.1016/j.kint.2018.11.025. [Epub ahead of print]

PMID:
30712923
10.

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial.

Inzucchi SE, Wanner C, Hehnke U, Zwiener I, Kaspers S, Clark D, George JT, Zinman B.

Diabetes Care. 2019 Apr;42(4):e53-e55. doi: 10.2337/dc18-1355. Epub 2019 Jan 31. No abstract available.

PMID:
30705060
11.

Differences in Dialysis Efficacy Have Limited Effects on Protein-Bound Uremic Toxins Plasma Levels over Time.

Krieter DH, Kerwagen S, Rüth M, Lemke HD, Wanner C.

Toxins (Basel). 2019 Jan 16;11(1). pii: E47. doi: 10.3390/toxins11010047.

12.

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators.

Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352.

PMID:
30586723
13.

Hot topics in Fabry disease.

Cairns T, Müntze J, Gernert J, Spingler L, Nordbeck P, Wanner C.

Postgrad Med J. 2018 Dec;94(1118):709-713. doi: 10.1136/postgradmedj-2018-136056. Epub 2018 Dec 17. Review.

PMID:
30559317
14.

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, George JT, Green JB, Landray MJ, Baigent C, Wanner C.

Clin Kidney J. 2018 Dec;11(6):749-761. doi: 10.1093/ckj/sfy090. Epub 2018 Oct 25. Review.

15.

Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year.

Müntze J, Gensler D, Maniuc O, Liu D, Cairns T, Oder D, Hu K, Lorenz K, Frantz S, Wanner C, Nordbeck P.

Clin Pharmacol Ther. 2018 Dec 3. doi: 10.1002/cpt.1321. [Epub ahead of print]

PMID:
30506669
16.

Lancet Countdown paper: what does it mean for nephrology?

Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Massy Z, Rychlík I, Soler MJ, Spasovski G, Stevens K, Wanner C, Zoccali C.

Nephrol Dial Transplant. 2019 Jan 1;34(1):4-6. doi: 10.1093/ndt/gfy369. No abstract available.

PMID:
30496519
17.

Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.

Dale DC, Bolyard AA, Marrero T, Kelley ML, Makaryan V, Tran E, Leung J, Boxer LA, Kishnani PS, Austin S, Wanner C, Ferrecchia IA, Khalaf D, Maze D, Kurtzberg J, Zeidler C, Welte K, Weinstein DA.

Curr Opin Hematol. 2019 Jan;26(1):16-21. doi: 10.1097/MOH.0000000000000474.

PMID:
30451720
18.

Variations in cardiovascular risk factors in people with and without migration background in Germany - Results from the STAAB cohort study.

Morbach C, Gelbrich G, Tiffe T, Eichner F, Wagner M, Heuschmann PU, Störk S; STAAB consortium, Frantz S, Maack C, Ertl G, Fassnacht M, Wanner C, Leyh R, Volkmann J, Deckert J, Faller H, Jahns R.

Int J Cardiol. 2018 Oct 30. pii: S0167-5273(18)34130-5. doi: 10.1016/j.ijcard.2018.10.098. [Epub ahead of print]

PMID:
30420145
19.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators.

JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.

PMID:
30418475
20.

The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts.

Germain DP, Arad M, Burlina A, Elliott PM, Falissard B, Feldt-Rasmussen U, Hilz MJ, Hughes DA, Ortiz A, Wanner C, Weidemann F, Spada M.

Mol Genet Metab. 2018 Sep 27. pii: S1096-7192(18)30192-6. doi: 10.1016/j.ymgme.2018.09.007. [Epub ahead of print] Review.

21.

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial.

Kadowaki T, Nangaku M, Hantel S, Okamura T, von Eynatten M, Wanner C, Koitka-Weber A.

J Diabetes Investig. 2018 Nov 9. doi: 10.1111/jdi.12971. [Epub ahead of print]

22.

Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.

Lenders M, Neußer LP, Rudnicki M, Nordbeck P, Canaan-Kühl S, Nowak A, Cybulla M, Schmitz B, Lukas J, Wanner C, Brand SM, Brand E.

J Am Soc Nephrol. 2018 Dec;29(12):2879-2889. doi: 10.1681/ASN.2018070740. Epub 2018 Nov 1.

PMID:
30385651
23.

Cardiac Troponins for the Diagnosis of Acute Myocardial Infarction in Chronic Kidney Disease.

Kraus D, von Jeinsen B, Tzikas S, Palapies L, Zeller T, Bickel C, Fette G, Lackner KJ, Drechsler C, Neumann JT, Baldus S, Blankenberg S, Münzel T, Wanner C, Zeiher AM, Keller T.

J Am Heart Assoc. 2018 Oct 2;7(19):e008032. doi: 10.1161/JAHA.117.008032.

24.

Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".

Wanner C, von Eynatten M, Zinman B.

Circulation. 2018 Aug 21;138(8):850-851. doi: 10.1161/CIRCULATIONAHA.118.035881. No abstract available.

PMID:
30359123
25.

Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease.

Scheppach JB, Raff U, Toncar S, Ritter C, Klink T, Störk S, Wanner C, Schlieper G, Saritas T, Reinartz SD, Floege J, Janka R, Uder M, Schmieder RE, Eckardt KU, Schneider MP.

Hypertension. 2018 Oct;72(4):929-936. doi: 10.1161/HYPERTENSIONAHA.118.11608.

PMID:
30354716
26.

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.

Inzucchi SE, Kosiborod M, Fitchett D, Wanner C, Hehnke U, Kaspers S, George JT, Zinman B.

Circulation. 2018 Oct 23;138(17):1904-1907. doi: 10.1161/CIRCULATIONAHA.118.035759. No abstract available.

PMID:
30354665
28.

Farewell Editorial.

Burrowes JD, Wanner C.

J Ren Nutr. 2018 Nov;28(6):367-368. doi: 10.1053/j.jrn.2018.07.002. No abstract available.

PMID:
30348258
29.

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators.

J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12.

PMID:
30314978
30.

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.

Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J, Bayes-Genis A, Brutsaert D, Bugger H, Clarke K, Cosentino F, De Keulenaer G, Dei Cas A, González A, Huelsmann M, Iaccarino G, Lunde IG, Lyon AR, Pollesello P, Rena G, Riksen NP, Rosano G, Staels B, van Laake LW, Wanner C, Farmakis D, Filippatos G, Ruschitzka F, Seferovic P, de Boer RA, Heymans S.

Eur Heart J. 2018 Dec 21;39(48):4243-4254. doi: 10.1093/eurheartj/ehy596. No abstract available.

31.

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.

Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S.

Lancet. 2018 Oct 13;392(10155):1311-1320. doi: 10.1016/S0140-6736(18)31652-0. Epub 2018 Oct 4.

PMID:
30293769
32.

Correction: Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study.

Schneider MP, Hilgers KF, Schmid M, Hübner S, Nadal J, Seitz D, Busch M, Haller H, Köttgen A, Kronenberg F, Baid-Agrawal S, Schlieper G, Schultheiss U, Sitter T, Sommerer C, Titze S, Meiselbach H, Wanner C, Eckardt KU; GCKD Study Investigators.

PLoS One. 2018 Sep 13;13(9):e0204340. doi: 10.1371/journal.pone.0204340. eCollection 2018.

33.

Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study.

Reinecke H, Jürgensmeyer S, Engelbertz C, Gerss J, Kirchhof P, Breithardt G, Bauersachs R, Wanner C.

BMJ Open. 2018 Sep 10;8(9):e022690. doi: 10.1136/bmjopen-2018-022690.

34.

Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition.

Prischl FC, Wanner C.

Kidney Int Rep. 2018 Apr 22;3(5):1030-1038. doi: 10.1016/j.ekir.2018.04.008. eCollection 2018 Sep. Review.

35.

SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.

Wanner C, Marx N.

Diabetologia. 2018 Oct;61(10):2134-2139. doi: 10.1007/s00125-018-4678-z. Epub 2018 Aug 22. Review.

PMID:
30132035
36.

Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study.

Schneider MP, Hilgers KF, Schmid M, Hübner S, Nadal J, Seitz D, Busch M, Haller H, Köttgen A, Kronenberg F, Baid-Agrawal S, Schlieper G, Schultheiss U, Sitter T, Sommerer C, Titze S, Meiselbach H, Wanner C, Eckardt KU; GCKD Study Investigators.

PLoS One. 2018 Aug 20;13(8):e0202604. doi: 10.1371/journal.pone.0202604. eCollection 2018. Erratum in: PLoS One. 2018 Sep 13;13(9):e0204340.

37.

The ABCs in the Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease: An Introductory Remark on Expert Perspectives.

Wanner C.

Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1421-1422. doi: 10.2215/CJN.09090718. Epub 2018 Aug 15. No abstract available.

PMID:
30111587
38.

Characterization of vertigo and hearing loss in patients with Fabry disease.

Köping M, Shehata-Dieler W, Schneider D, Cebulla M, Oder D, Müntze J, Nordbeck P, Wanner C, Hagen R, Schraven SP.

Orphanet J Rare Dis. 2018 Aug 15;13(1):137. doi: 10.1186/s13023-018-0882-7.

39.

Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease.

Liu D, Oder D, Salinger T, Hu K, Müntze J, Weidemann F, Herrmann S, Ertl G, Wanner C, Frantz S, Störk S, Nordbeck P.

Open Heart. 2018 Jul 12;5(2):e000803. doi: 10.1136/openhrt-2018-000803. eCollection 2018.

40.

European expert consensus statement on therapeutic goals in Fabry disease.

Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymańska A, Tøndel C, Viana-Baptista M, Weidemann F, Hilz MJ.

Mol Genet Metab. 2018 Jul;124(3):189-203. doi: 10.1016/j.ymgme.2018.06.004. Epub 2018 Jun 12. Review.

PMID:
30017653
41.

Detection of blood Gb3 deposits as a new tool for diagnosis and therapy monitoring in patients with classic Fabry disease.

Üçeyler N, Böttger J, Henkel L, Langjahr M, Mayer C, Nordbeck P, Wanner C, Sommer C.

J Intern Med. 2018 Oct;284(4):427-438. doi: 10.1111/joim.12801. Epub 2018 Jul 4.

PMID:
29974530
42.

The impact of symptoms on health-related quality of life in elderly pre-dialysis patients: effect and importance in the EQUAL study.

Voskamp PWM, van Diepen M, Evans M, Caskey FJ, Torino C, Postorino M, Szymczak M, Klinger M, Wallquist C, van de Luijtgaarden MWM, Chesnaye NC, Wanner C, Jager KJ, Dekker FW; EQUAL Study Investigators.

Nephrol Dial Transplant. 2018 Jun 22. doi: 10.1093/ndt/gfy167. [Epub ahead of print]

PMID:
29939304
43.

Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Wanner C, Herzog CA, Turakhia MP; Conference Steering Committee.

Kidney Int. 2018 Aug;94(2):231-234. doi: 10.1016/j.kint.2018.05.005. Epub 2018 Jun 21. No abstract available.

PMID:
29935952
44.

Uraemic symptom burden and clinical condition in women and men of ≥65 years of age with advanced chronic kidney disease: results from the EQUAL study.

van de Luijtgaarden MWM, Caskey FJ, Wanner C, Chesnaye NC, Postorino M, Janmaat CJ, Rao A, Torino C, Klinger M, Drechsler C, Heimburger O, Szymczak M, Evans M, Dekker FW, Jager KJ; EQUAL study investigators .

Nephrol Dial Transplant. 2018 Jun 13. doi: 10.1093/ndt/gfy155. [Epub ahead of print]

PMID:
29905848
45.

Cardiovascular Outcomes Reported in Hemodialysis Trials.

O'Lone E, Viecelli AK, Craig JC, Tong A, Sautenet B, Roy D, Herrington WG, Herzog CA, Jafar T, Jardine M, Krane V, Levin A, Malyszko J, Rocco MV, Strippoli G, Tonelli M, Wang AYM, Wanner C, Zannad F, Winkelmayer WC, Webster AC, Wheeler DC.

J Am Coll Cardiol. 2018 Jun 19;71(24):2802-2810. doi: 10.1016/j.jacc.2018.04.012. Review.

PMID:
29903353
46.

Value of the CHA2DS2-VASc score and Fabry-specific score for predicting new-onset or recurrent stroke/TIA in Fabry disease patients without atrial fibrillation.

Liu D, Hu K, Schmidt M, Müntze J, Maniuc O, Gensler D, Oder D, Salinger T, Weidemann F, Ertl G, Frantz S, Wanner C, Nordbeck P.

Clin Res Cardiol. 2018 Dec;107(12):1111-1121. doi: 10.1007/s00392-018-1285-4. Epub 2018 May 24.

47.

Clinical impact of the alpha-galactosidase A gene single nucleotide polymorphism -10C>T: A single-center observational study.

Oder D, Liu D, Üçeyler N, Sommer C, Hu K, Salinger T, Müntze J, Petritsch B, Ertl G, Wanner C, Nordbeck P, Weidemann F.

Medicine (Baltimore). 2018 May;97(21):e10669. doi: 10.1097/MD.0000000000010669.

48.

The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts.

Spada M, Baron R, Elliott PM, Falissard B, Hilz MJ, Monserrat L, Tøndel C, Tylki-Szymańska A, Wanner C, Germain DP.

Mol Genet Metab. 2018 Apr 26. pii: S1096-7192(18)30186-0. doi: 10.1016/j.ymgme.2018.04.007. [Epub ahead of print] Review.

49.

Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy.

Wanner C, Germain DP, Hilz MJ, Spada M, Falissard B, Elliott PM.

Mol Genet Metab. 2018 Apr 11. pii: S1096-7192(17)30589-9. doi: 10.1016/j.ymgme.2018.04.004. [Epub ahead of print] No abstract available.

PMID:
29724657
50.

Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.

Zinman B, Inzucchi SE, Wanner C, Hehnke U, George JT, Johansen OE, Fitchett D; EMPA-REG OUTCOME® investigators.

Diabetologia. 2018 Jul;61(7):1522-1527. doi: 10.1007/s00125-018-4630-2. Epub 2018 Apr 30.

PMID:
29713728

Supplemental Content

Loading ...
Support Center